Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach
Twelve years after a widely quoted Cleveland Clinic study showed a staggering 99.6% failure rate for Alzheimer’s disease clinical candidates, the percentage has hardly budged.
But ImmunoBrain, an 11-year-old company, has generated early-stage clinical data showing success for a first-of-its-kind, immunotherapy-based approach to treating Alzheimer’s that goes beyond aiming at the two most common targets, amyloid plaques and tau neurofibrillary tangles.
ImmunoBrain develops treatments intended to address Alzheimer’s and other neurodegenerative diseases by restoring the body’s peripheral immune system to facilitate brain protection and repair. The company uses a novel approach that targets the peripheral immune system to break the vicious cycle between neuroinflammation developed in the brain with neurodegenerative diseases and the progressive decline in peripheral immune function that together derives disease progression.

That approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.
“It’s not just a disease of only accumulation of toxic protein,” Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer, told GEN. “We know now that the disease is dormant or asymptomatic for 10 to 20 years before symptoms are seen. Once symptoms are seen, the disease progression is driven not only by the amyloid plaque, but an additional major factor, local inflammation.”
“It’s not the primary cause, it’s not the trigger, but definitely a catalyzer,” said Schwartz, who is also a professor of neuroimmunology at the Weizmann Institute of Science in Rehovot, Israel.
Alzheimer’s starts in the brain, with the accumulated of the toxic proteins such as amyloid and tau. At this stage, local immune cells—microglia—within the brain, supported by the peripheral immune system, can help prevent or minimize damage to neurons, the brain’s functional cells. When the immune system ages and declines, its ability to help the brain is reduced, fueling the brain pathology.
That happens, says Schwartz, when the brain’s own immune cells known collectively as microglia become the source of inflammation.
Antibody approach
“Our approach is, we developed a new antibody that targets the inhibitory checkpoint, thereby we boost the level very transiently of immune cells that can facilitate a homing of immune repairing cells from the peripheral immune system to the brain. They are facilitating dampening the local inflammation and thereby creating a supportive milieu within the brain that can rescue neurons and synapses that are still healthy but not functioning well.”
Schwartz’s lab was first to show that the brain is not immune isolated, but tightly dependent on the immune system for its daily maintenance, daily function, protection and repair, as it is the gatekeeper of the brain: “The meaning of it is that aging of the brain reflects more the immunological aging than the chronological aging.”
ImmunoBrain’s lead program applies IBC-Ab002, a company-developed anti-PD-L1 monoclonal antibody engineered specifically for use in chronic neurodegenerative disease settings. Specifically, IBC-Ab002 is engineered for transient, intermittent blockade of the PD-1/PD-L1 pathway. The transient checkpoint blockade allows for triggering of the immune system, initiating an immune cascade by facilitating the homing of immune-repairing monocytes and regulatory T cells (immune system regulators) that clear senescent microglia, and resolves inflammation, thereby helping the brain protection and repair.
IBC-Ab002 combines high-affinity PD-L1 binding with Fc effector silencing and reduced FcRn binding modification designed to eliminate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Positive first-in-human data
At the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London, and in a study published in Nature Medicine, ImmunoBrain shared positive data for IBC-Ab002 from a Phase Ib first-in-human study (NCT05551741) in patients with early Alzheimer’s. Forty patients were enrolled across five ascending dose cohorts (1–30 mg kg−1), with dosing administered four times at 3-month intervals, and patients followed up for one year. The study’s primary endpoints were safety and tolerability.
The data showed the antibody to have a half-life of approximately four days across all dose cohorts. IBC-Ab002 generated encouraging fluid biomarker data, as well as reductions of biomarkers associated with neuronal and synaptic damage, with no brain hemorrhaging or ARIA (amyloid-related imaging abnormalities) seen.
Exploratory CSF biomarker analyses at 48 weeks showed reductions in neurogranin (−23.1%), tTau (−12.4%) and pTau181 (−11.0%) at the 30 mg kg−1 dose compared with pooled placebo, with intraindividual consistency across the three markers in participants treated with IBC-Ab002. A pre-synaptic biomarker, VAMP2, showed a similar trend to neurogranin, with strong correlation between individual responses to both markers.
‘Beyond our expectation’
“The biomarkers show an encouraging result, mainly the Neurogranin that is Alzheimer’s characteristic marker and prediction of cognitive performance. Yet, we cannot speak about statistical significance because of the small number of patients and the short duration of the follow-up, but it was beyond our expectation to see from such a small study,” said Schwartz, one of three corresponding authors on the Nature Medicine paper.
“IBC-Ab002 is intended to transiently re-engage the peripheral immune system, whose ability to support the brain declines with aging, thereby restoring its capacity to protect the brain and dampen brain inflammatory processes,” Schwartz and colleagues wrote. “Because this strategy does not rely on directly targeting a specific brain proteinopathy, it has broader applicability across other chronic neurodegenerative conditions in which neuroinflammation contributes to disease progression.”
Schwartz said she and colleagues are planning a Phase IIb trial for which they have submitted paperwork to the FDA, and for which they are raising funds. That study would include a two-year follow-up of participants: “We are aiming to do a big study, very rigorous, with a very ambitious endpoint, so if successful, as it seems based on the Phase Ib, it may speed up approval of this drug and may be considered as a pivotal study.”
In September, Schwartz was corresponding author of another paper, which was published in Nature Neuroscience that showed in both a mouse model and in Alzheimer’s patients the body’s “factory” of the a potentially protective immune response—the production of monocyte-derived macrophages in the bone marrow and their recruitment to the brain—key processes that help protect against disease progression are compromised: “Our results reveal a dysfunction in bone marrow myelopoiesis in AD and reinforce the concept that AD progression is driven by maladaptive systemic immune processes.”
“We wanted to see whether the deficiency in homing of macrophages that we are boosting with the anti-PD-L1 is reflection of some impairment in the factory of these monocytes, which is in the bone room,” Schwartz said. “When we saw that there is really impairment in production of monocytes in the factory of the monocytes in the bone marrow, I was, wow, very excited, because it further supports the notion that disease is not just disease of the brain. Then we found that the cause of this impairment is elevation of type 1 interferon, which all of us produce when we are encountering viral infection.”
Type I interferon signaling is an essential part of the body’s natural protective immune response. However, when this response becomes chronic, Schwartz explained, its protective effects can turn harmful—transforming a friend into a foe.
“If you have an inflammation in the body, the immune system produces type 1 interferon to dampen inflammation. But if this type 1 interferon is chronically produced, it becomes an enemy of the bone marrow. And we found the same situation in mice and in humans,” Schwartz explained.
Earlier research
That finding was in sync with earlier research published in Science by Schwartz and colleagues in 2014, showing that aging of the brain in both humans and mice was also associated with type 1 interferon.
“And in a way, it’s also linking what we know, that viral infection can catalyze Alzheimer’s disease … It is more likely the uncontrolled immune response to the virus, rather than the virus itself, that causes the damage.” Schwartz added. “It’s not just a disease of the brain. The brain affects the immune system, the immune system is impaired, and they enter into a vicious cycle.”
Last month, ImmunoBrain named to its board Francis Collins, MD, PhD, whose tenure as NIH director from 2009 to 2021 is the longest of any presidentially appointed director of the agency.
“One of my jobs as NIH director was to look across the entire field of biomedical research and say, ‘Are there some really serious gaps here that need to be filled?’ Alzheimer’s disease, because it is so common and so devastating for individuals and their families, obviously has been a high priority for research, particularly through the National Institute on Aging,” Collins recalled. “But despite massive efforts, it didn’t feel like we were necessarily making progress of the groundbreaking type that people were hoping for.”
The Cleveland Clinic’s reported 99.6% failure rate showed little improvement in a 2022 study that found a 98% failure rate among candidates studied in Phase II and III trials. And a study by Michael A.S. Guth, PhD, JD, published in August blamed the high failure rate on “structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action across 567 Phase II and Phase III Alzheimer’s trials from 2010 to 2026.”
“The 567-trial record constitutes a structural verdict on a model of drug development that was never designed to solve a problem of this complexity,” Guth asserted. “The uniformity of negative results across all mechanism categories—amyloid, tau, neuroinflammation, metabolic, and synaptic—points toward deeper problems of disease definition, intervention timing, and endpoint validity that institutional and financial pressures have prevented the field from confronting.”

Recalled Collins: “Most of the efforts I saw happening as NIH director were in terms of developing and testing monoclonal antibodies against amyloid. While they provided some positive signals, they certainly didn’t provide the breakthrough benefit that people had hoped for.”
There must be something more going on here, Collins concluded. Maybe genetic research could provide clues? Studies of large numbers of affected and unaffected individuals using the GWAS (genome-wide association study) approach have now pointed to more than 100 such signals. The dominant pathway relates to microglia and innate immunity.
Yet the field of Alzheimer’s research has done relatively little to explore that area therapeutically, and remains focused, he said, primarily on amyloid and tau and lipids such as ApoE: “The field seems to be stuck on the amyloid hypothesis, but so far that’s not curing people or significantly preventing progression like we hoped.”
Milestones and growing pipeline
Alzheimer’s drug development has achieved several milestones during this decade.
Biogen and Eisai made history in 2021 when the FDA approved their controversial human immunoglobulin gamma 1 (IgG1) monoclonal antibody Aduhelm® (aducanumab-avwa) as the first therapy indicated for reducing clinical decline in people with Alzheimer’s disease, and the first therapy to tie improved clinical outcomes to removing amyloid beta. But Aduhelm sales never matched forecasts and failed to the drug failed to obtain coverage from the Centers for Medicare and Medicaid Services (CMS).
In 2024, Biogen halted development and commercialization of Aduhelm in order to shift resources to other Alzheimer’s treatments—a year after the companies’ Leqembi® (lecanumab-irmb) became the first disease-modifying therapy to receive full FDA approval for patients with mild cognitive impairment or mild dementia.
The FDA has since approved a weekly subcutaneous maintenance dose last year and a subcutaneous starter dose in July, the latter marketed as Leqembi Iklik. The new subcutaneous doses have propelled Leqembi sales to finally outpacing sales forecasts after a slow start for the drug. During the third quarter, Eisai reported $202 million in global sales, up 67% from $121 million in Q3 2025. That includes $68 million recorded by Biogen in “Alzheimer’s collaboration” revenue—the sum of Biogen’s 50% share of net revenue and cost of sales, including royalties, from its Leqembi collaboration.
Another milestone occurred when Eli Lilly won FDA approval in 2024 for Kisunla® (donanemab-azbt), a once-monthly injection treatment indicated for adults with early symptomatic Alzheimer’s, including mild cognitive impairment or mild dementia stage of disease with confirmed amyloid pathology. Kisunla was approved as the first amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.
Among current Alzheimer’s candidates in Phase III development, AriBio on Monday trumpeted data from the Phase III POLARIS-AD trial (NCT05531526) at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Boston through Thursday. The data showed that its once-daily oral small molecule phosphodiesterase-5 (PDE5) inhibitor AR1001 showed statistically significant treatment difference of −0.44 points versus placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 52 (p=0.0266), representing 31% slowing of clinical decline.
But in the trial’s overall 1,535-participant population, the treatment difference vs. placebo was −0.11 points (p=0.4015), which did not reach statistical significance. AriBio said it plans to discuss the results with the FDA before deciding next steps.
AR1001 is among numerous Phase III Alzheimer’s candidates. Two examples:
- Roche and its Genentech subsidiary anticipate primary completion in February 2028 for the TRONTIER1 (NCT07169578) and TRONTIER2 (NCT07170150) trials for their anti-amyloid monoclonal antibody trontinemab (RO7126209) in 2028. A prevention study, PrevenTRON (NCT07717411), estimates primary data completion in 2032.
- Eli Lilly expects releasing data in 2029 from its Phase III TRAILRUNNER-ALZ 3 trial (NCT06653153) assessing its beta-amyloid plaque targeting next-gen antibody remternetug (LY3372993).
‘Pretty excited’
“The ImmunoBrain approach is, for me, a completely compelling and novel approach. It is built on a sweeping redefinition of what the fundamental problems are with Alzheimer’s disease. It builds on basic science data that implicates the immune system as a major player in progression, and even as a signal for aging itself,” Collins explained. “I am pretty excited about that.”
Collins said his departure from the NIH—a sudden retirement in February 2025 after 32 years with the agency—offers him the opportunity to serve on company boards like that of ImmunoBrain.
“The need for progress in Alzheimer’s disease has been compelling to me for years. In this new life chapter, I wanted to get more engaged to see if I could be helpful in some way. The data that Michal and her lab have generated over 25 years, building this case for a critical role of the immune system, points to a wholly new vision of the pathogenesis of this common and devastating disease. Now that we see the encouraging result of biomarkers in a Phase Ib trial, published in a highly regarded peer-reviewed journal, it looks like we’re on the right track,” Collins said.
“I am now really excited about seeing this go forward to a Phase IIb trial with a clinical endpoint. The question is: can we show that this intervention changes the course of the illness?” the former NIH director added. “It will take a big push to answer that. It’s going to cost a lot of money. But of all the things I look at right now that are happening in Alzheimer’s, this feels like an exceptionally novel, encouraging, and potentially groundbreaking way to look at the disease in a new way that hasn’t been adequately explored before.”
The post Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
